Advertisement
UK markets closed

  • FTSE 100

    8,139.83
    +60.97 (+0.75%)
     

  • FTSE 250

    19,824.16
    +222.18 (+1.13%)
     

  • AIM

    755.28
    +2.16 (+0.29%)
     

  • GBP/EUR

    1.1679
    +0.0022 (+0.19%)
     

  • GBP/USD

    1.2491
    -0.0020 (-0.16%)
     

  • Bitcoin GBP

    51,225.96
    -747.84 (-1.44%)
     

  • CMC Crypto 200

    1,331.08
    -65.46 (-4.69%)
     

  • S&P 500

    5,099.96
    +51.54 (+1.02%)
     

  • DOW

    38,239.66
    +153.86 (+0.40%)
     

  • CRUDE OIL

    83.68
    +0.11 (+0.13%)
     

  • GOLD FUTURES

    2,349.30
    +6.80 (+0.29%)
     

  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     

  • HANG SENG

    17,651.15
    +366.61 (+2.12%)
     

  • DAX

    18,161.01
    +243.73 (+1.36%)
     

  • CAC 40

    8,088.24
    +71.59 (+0.89%)
     
PROPERTY:

9 luxury homes to consider if money is no object

Ever thought about what a multimillion pound budget would buy you?

GW Pharmaceuticals Beats on Revenue, Bottom Line for Q4

Eric Volkman, The Motley Fool
·2-min read
GW Pharmaceuticals Beats on Revenue, Bottom Line for Q4

GW Pharmaceuticals (NASDAQ: GWPH) has released what is very possibly its final earnings report as an independent company. On Tuesday, the maker of drugs derived from cannabis published its fourth-quarter results, which revealed that it earned $148 million in revenue for the period. Nearly all of GW Pharmaceuticals' revenue for the period derived from its top drug, Epidiolex, which treats seizures arising from two rare forms of childhood epilepsy, plus the genetic disorder tuberous sclerosis complex.

Continue reading